Can overexpression of parkin provide a novel strategy for neuroprotection in Parkinson's disease?

Experimental Neurology

Volumn 212, Issue 2, 2008, Pages 258-260

  Ulusoy, Ayse ^a   Kirik, Deniz ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

synuclein; Dopamine; Glial cell line derived neurotrophic factor; Neurodegeneration; Substantia nigra

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; DOPAMINE TRANSPORTER; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LENTIVIRUS VECTOR; NEUROTROPHIC FACTOR; NEURTURIN; OXIDOPAMINE; PARKIN;

DISEASE ACTIVITY; DISEASE COURSE; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; GENE ACTIVITY; GENE MUTATION; GENE OVEREXPRESSION; GENE TRANSFER; HUMAN; MOTOR DYSFUNCTION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HUMANS; PARKINSON DISEASE; UBIQUITIN-PROTEIN LIGASES;

EID: 47549084043     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2008.04.026     Document Type: Review

References (39)

1. Cha G.H., Kim S., Park J., Lee E., Kim M., Lee S.B., Kim J.M., Chung J., and Cho K.S. Parkin negatively regulates JNK pathway in the dopaminergic neurons of Drosophila. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 10345-10350
2. Chung K.K., Zhang Y., Lim K.L., Tanaka Y., Huang H., Gao J., Ross C.A., Dawson V.L., and Dawson T.M. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat. Med. 7 (2001) 1144-1150
3. Doss-Pepe E.W., Chen L., and Madura K. Alpha-synuclein and parkin contribute to the assembly of ubiquitin lysine 63-linked multiubiquitin chains. J. Biol. Chem. 280 (2005) 16619-16624
4. Georgievska B., Kirik D., Rosenblad C., Lundberg C., and Bjorklund A. Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector. Neuroreport 13 (2002) 75-82
5. Eslamboli A., Georgievska B., Ridley R.M., Baker H.F., Muzyczka N., Burger C., Mandel R.J., Annett L., and Kirik D. Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease. J. Neurosci. 25 (2005) 769-777
6. Goldberg M.S., Fleming S.M., Palacino J.J., Cepeda C., Lam H.A., Bhatnagar A., Meloni E.G., Wu N., Ackerson L.C., Klapstein G.J., Gajendiran M., Roth B.L., Chesselet M.F., Maidment N.T., Levine M.S., and Shen J. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J. Biol. Chem. 278 (2003) 43628-43635
7. Hamilton J.F., Morrison P.F., Chen M.Y., Harvey-White J., Pernaute R.S., Phillips H., Oldfield E., and Bankiewicz K.S. Heparin coinfusion during convection-enhanced delivery (CED) increases the distribution of the glial-derived neurotrophic factor (GDNF) ligand family in rat striatum and enhances the pharmacological activity of neurturin. Exp. Neurol. 168 (2001) 155-161
8. Hampe C., Ardila-Osorio H., Fournier M., Brice A., and Corti O. Biochemical analysis of Parkinson's disease-causing variants of Parkin, an E3 ubiquitin-protein ligase with monoubiquitylation capacity. Hum. Mol. Genet. 15 (2006) 2059-2075
9. Hasegawa T., Treis A., Patenge N., Fiesel F.C., Springer W., and Kahle P.J. Parkin protects against tyrosinase-mediated dopamine neurotoxicity by suppressing stress-activated protein kinase pathways. J. Neurochem. 105 (2008) 1700-1715
10. Henn I.H., Bouman L., Schlehe J.S., Schlierf A., Schramm J.E., Wegener E., Nakaso K., Culmsee C., Berninger B., Krappmann D., Tatzelt J., and Winklhofer K.F. Parkin mediates neuroprotection through activation of IkappaB kinase/nuclear factor-kappaB signaling. J. Neurosci. 27 (2007) 1868-1878
11. Horger B.A., Nishimura M.C., Armanini M.P., Wang L.C., Poulsen K.T., Rosenblad C., Kirik D., Moffat B., Simmons L., Johnson Jr. E., Milbrandt J., Rosenthal A., Bjorklund A., Vandlen R.A., Hynes M.A., and Phillips H.S. Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. J. Neurosci. 18 (1998) 4929-4937
12. Hoffer B.J., Hoffman A., Bowenkamp K., Huettl P., Hudson J., Martin D., Lin L.F., and Gerhardt G.A. Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci. Lett. 182 (1994) 107-111
13. Imai Y., Soda M., and Takahashi R. Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J. Biol. Chem. 275 (2000) 35661-35664
14. Imai Y., Soda M., Inoue H., Hattori N., Mizuno Y., and Takahashi R. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell 105 (2001) 891-902
15. Jiang H., Jiang Q., and Feng J. Parkin increases dopamine uptake by enhancing the cell surface expression of dopamine transporter. J. Biol. Chem. 279 (2004) 54380-54386
16. Kearns C.M., Cass W.A., Smoot K., Kryscio R., and Gash D.M. GDNF protection against 6-OHDA: time dependence and requirement for protein synthesis. J. Neurosci. 17 (1997) 7111-7118
17. Kirik D., and Bjorklund A. Parkinson's disease: Viral vector delivery of parkin generates model results in rats. Gene Ther. 12 (2005) 27-729
18. Kirik D., Rosenblad C., and Bjorklund A. Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor. Eur. J. Neurosci. 12 (2000) 3871-3882
19. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y., and Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392 (1998) 605-608
20. Kordower J.H., Emborg M.E., Bloch J., Ma S.Y., Chu Y., Leventhal L., McBride J., Chen E.Y., Palfi S., Roitberg B.Z., Brown W.D., Holden J.E., Pyzalski R., Taylor M.D., Carvey P., Ling Z., Trono D., Hantraye P., Deglon N., and Aebischer P. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290 (2000) 767-773
21. Kordower J.H., Herzog C.D., Dass B., Bakay R.A., Stansell III J., Gasmi M., and Bartus R.T. Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann. Neurol. 60 (2006) 706-715
22. Lim K.L., Chew K.C., Tan J.M., Wang C., Chung K.K., Zhang Y., Tanaka Y., Smith W., Engelender S., Ross C.A., Dawson V.L., and Dawson T.M. Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation. J. Neurosci. 25 (2005) 2002-2009
23. Lo Bianco C., Deglon N., Pralong W., and Aebischer P. Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease. Neurobiol. Dis. 17 (2004) 283-289
24. Lo Bianco C., Schneider B.L., Bauer M., Sajadi A., Brice A., Iwatsubo T., and Aebischer P. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 17510-17515
25. Manfredsson F.P., Burger C., Sullivan L.F., Muzyczka N., Lewin A.S., and Mandel R.J. rAAV-mediated nigral human parkin over-expression partially ameliorates motor deficits via enhanced dopamine neurotransmission in a rat model of Parkinson's disease. Exp. Neurol. 207 (2007) 289-301
26. Matsuda N., Kitami T., Suzuki T., Mizuno Y., Hattori N., and Tanaka K. Diverse effects of pathogenic mutations of Parkin that catalyze multiple monoubiquitylation in vitro. J. Biol. Chem. 281 (2006) 3204-3209
27. Paterna J.C., Leng A., Weber E., Feldon J., and Bueler H. DJ-1 and Parkin modulate dopamine-dependent behavior and inhibit MPTP-induced nigral dopamine neuron loss in mice. Mol. Ther. 15 (2007) 698-704
28. Periquet M., Latouche M., Lohmann E., Rawal N., De Michele G., Ricard S., Teive H., Fraix V., Vidailhet M., Nicholl D., Barone P., Wood N.W., Raskin S., Deleuze J.F., Agid Y., Durr A., and Brice A. Parkin mutations are frequent in patients with isolated early-onset parkinsonism. Brain 126 (2003) 1271-1278
29. Poole A.C., Thomas R.E., Andrews L.A., McBride H.M., Whitworth A.J., and Pallanck L.J. The PINK1/Parkin pathway regulates mitochondrial morphology. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 1638-1643
30. Rosenblad C., Kirik D., Devaux B., Moffat B., Phillips H.S., and Bjorklund A. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle. Eur. J. Neurosci. 11 (1999) 1554-1566
31. Rosenblad C., Georgievska B., and Kirik D. Long-term striatal overexpression of GDNF selectively downregulates tyrosine hydroxylase in the intact nigrostriatal dopamine system. Eur. J. Neurosci. 17 (2003) 260-270
32. Shimura H., Schlossmacher M.G., Hattori N., Frosch M.P., Trockenbacher A., Schneider R., Mizuno Y., Kosik K.S., and Selkoe D.J. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 293 (2001) 263-269
33. Tomac A., Lindqvist E., Lin L.F., Ogren S.O., Young D., Hoffer B.J., and Olson L. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373 (1995) 335-339
34. Vercammen L., Van der Perren A., Vaudano E., Gijsbers R., Debyser Z., Van den Haute C., and Baekelandt V. Parkin protects against neurotoxicity in the 6-hydroxydopamine rat model for Parkinson's disease. Mol. Ther. 14 (2006) 716-723
35. Von Coelln R., Thomas B., Savitt J.M., Lim K.L., Sasaki M., Hess E.J., Dawson V.L., and Dawson T.M. Loss of locus coeruleus neurons and reduced startle in parkin null mice. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 10744-10749
36. Yamada M., Mizuno Y., and Mochizuki H. Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease. Hum. Gene Ther. 16 (2005) 262-270
37. Yang Y., Nishimura I., Imai Y., Takahashi R., and Lu B. Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila. Neuron 37 (2003) 911-924
38. Zhang Y., Gao J., Chung K.K., Huang H., Dawson V.L., and Dawson T.M. Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 13354-13359
39. Zhu X.R., Maskri L., Herold C., Bader V., Stichel C.C., Gunturkun O., and Lubbert H. Non-motor behavioural impairments in parkin-deficient mice. Eur. J. Neurosci. 26 (2007) 1902-1911